The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Orchard Therapeutics' OTL-203, an ex vivo autologous hematopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I). Source: Seeking Alpha 28/09/2020